Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas15.45 M17.83 M18.14 M19.17 M16.1 M17.14 M17.14 MPesquisa e desenvolvimento2.47 M2.75 M3.63 M5.03 M3.87 M3.03 M3.03 MLucro operacional-13.29 M-13.83 M-15.56 M-15.11 M-10.46 M-13.33 M-13.33 MLucro não operacional, total-2.53 M4.06 M476 K-86 K-870 K1.63 M1.63 MDespesa com juros, líquida de juros capitalizados139 K113 K156 K302 K269 K309 K309 KReceitas não operacionais, líquidas das despesas com juros-3.66 M4.83 M350 K-325 K-1.14 M1.35 M1.35 MReceitas/despesas incomuns990 K-884 K-30 K-63 K-1 000-26 K-26 KLucro antes dos impostos-15.89 M-9.76 M-15.08 M-15.2 M-11.33 M-11.7 M-18.87 MParticipação no lucro-66 K0—————Impostos000-4.27 M-1.56 M0—Participação de minoritários———————Outras receitas/despesas após impostos—-134 K18 K0———Lucro líquido antes das operações descontinuadas-15.82 M-9.76 M-15.08 M-15.2 M-11.33 M-11.7 M-11.7 MOperações descontinuadas———————Lucro líquido-15.82 M-9.76 M-15.08 M-15.2 M-11.33 M-11.7 M-11.7 MAjuste de diluição—————00Dividendos de ações preferenciais—————226 K226 KLucro líquido diluído disponível aos acionistas-15.82 M-10.79 M-15.08 M-15.2 M-11.33 M-11.92 M-11.92 MLucro básico por ação-33.15-12-17.4-16.5-8.4-4.91-4.91Lucro diluído por ação-33.15-13.2-17.4-16.5-8.43-4.91-4.91Número médio de ações básicas477.6 K812.87 K864.13 K924.47 K1.34 M2.43 M8.91 MAções diluídas477.6 K817.93 K864.13 K924.47 K1.34 M2.43 M8.91 MEBITDA-12.67 M-13.27 M-14.67 M-13.41 M-8.85 M-11.75 M-11.75 MEBIT-13.29 M-13.83 M-15.56 M-15.11 M-10.46 M-13.33 M-13.33 MCusto da receita3.81 M4.5 M6.7 M9.2 M8.41 M5.95 M5.95 MOutros componentes do custo———————Amortização e depreciação (fluxo de caixa)620 K561 K887 K1.7 M1.61 M1.57 M1.57 M
Ekso Bionics Holdings Inc
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community.